In conclusion, given the unclear etiology of PD in clinical practice, further exploration of the molecular mechanisms by which GLP-1 and its analogs influence mitochondrial function and dopamine homeostasis in PD treatment may provide new insights for preventing PD in T2DM patients and offer potential targets for clinical relief and treatment of PD. The gene discussed is GCG; the disease is Parkinson disease.